OpenAlex topic

Cancer therapeutics and mechanisms

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 1,544 works 40 author topics

Works

1,544 works

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes 2021
YÖKSİS SJR Q2 JCR Q1 OpenAlex top 1% OpenAlex 99.9%
In December 2019, COVID-19 epidemic was described in Wuhan, China, and the infection has spread widely affecting hundreds of thousands. Herein, an effort was made to identify commercially available drugs in order to repurpose them against coronavirus by the means of structure-based virtual screening. In addition, ZINC…
- KEMAL YELEKÇİ
Luotonin A A Naturally Occurring Human DNA Topoisomerase I Poison 2003
YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 92.9%
Luotonin A is a pyrroloquinazolinoquinoline alkaloid isolated from the Chinese herbal medicinal plant Peganum nigellastrum. Although previously shown to exhibit cytotoxicity against the murine leukemia P-388 cell line, the mechanism of action of luotonin A is unknown. Presently, we demonstrate that luotonin A stabiliz…
- ALİ ÇAĞIR
Synthesis and structure–activity relationships of new antimicrobial active multisubstituted benzazole derivatives 2004
OpenAlex top 10% OpenAlex 95.2%
No abstract yet.
- İLKAY YILDIZ
Synthesis and biological activities of diflunisal hydrazide–hydrazones 2003
OpenAlex 82.6%
No abstract yet.
Synthesis and biological activities of diflunisal hydrazide hydrazones 2003
YÖKSİS SJR Q1 JCR Q2 OpenAlex 82.6%
No abstract yet.
- FİKRETTİN ŞAHİN
Natural Products and Synthetic Analogs as a Source of Antitumor Drugs 2019
YÖKSİS SJR Q1 JCR Q2 OpenAlex top 1% OpenAlex 99.5%
Cancer is a heterogeneous disease and one of the major issues of health concern, especially for the public health system globally. Nature is a source of anticancer drugs with abundant pool of diverse chemicals and pharmacologically active compounds. In recent decade, some natural products and synthetic analogs have be…
- TUĞBA TÜMER
Synthesis and structure antituberculosis activity relationship of 1H indole 2 3 dione derivatives 2007
YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 94.0%
New series of 5-fluoro-1H-indole-2,3-dione-3-thiosemicarbazones 2a-k and 5-fluoro-1-morpholino/piperidinomethyl-1H-indole-2,3-dione-3-thiosemicarbazones 3a-r were synthesized. The structures of the synthesized compounds were confirmed by spectral data, elemental and single crystal X-ray diffraction analysis. The new 5…
- FATMA KANDEMİRLİ
Synthesis and structure antituberculosis activity relationship of 1H indole 2 3 dione derivatives 2007
YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 93.9%
New series of 5-fluoro-1H-indole-2,3-dione-3-thiosemicarbazones 2a-k and 5-fluoro-1-morpholino/piperidinomethyl-1H-indole-2,3-dione-3-thiosemicarbazones 3a-r were synthesized. The structures of the synthesized compounds were confirmed by spectral data, elemental and single crystal X-ray diffraction analysis. The new 5…
- FATMA KANDEMİRLİ
- FİLİZ BETÜL KAYNAK
Synthesis and antimycobacterial activity of some coupling products from 4 aminobenzoic acid hydrazones 1999
YÖKSİS SJR Q1 JCR Q3 OpenAlex 88.9%
No abstract yet.
- ŞÜKRİYE GÜNİZ KÜÇÜKGÜZEL
Synthesis and antimycobacterial activity of some coupling products from 4 aminobenzoic acid hydrazones 1999
YÖKSİS SJR Q1 JCR Q3 OpenAlex 88.9%
No abstract yet.
- İLKAY KÜÇÜKGÜZEL
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. 1998
OpenAlex top 10% OpenAlex 92.8%
PURPOSE: To evaluate the feasibility of administering biricodar (VX-710; Incel, Vertex Pharmaceuticals Inc, Cambridge, MA), an agent that modulates multidrug resistance (MDR) conferred by overexpression of both the multidrug resistance gene product (MDR1) P-glycoprotein and the MDR-associated protein (MRP) in vitro, i…
High dose chemotherapy and autologous haematopoietic stem cell rescue for children with high risk neuroblastoma 2015
YÖKSİS OpenAlex top 10% OpenAlex 98.6%
BACKGROUND: Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High-dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival. This review is the sec…
- BİLGEHAN YALÇIN

Academicians

40 academicians